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Novelty
In this pooled analysis of five population-based case-control studies from different geographical areas (United Kingdom, Denmark,
Northern California and Hawaii), we observed a significant association of the VDR rs2228570 polymorphism with invasive ovarian
carcinoma, particularly among younger women (age < 50 years old). The vitamin D signaling pathway is involved in a wide variety of
biological processes, including cell proliferation, differentiation and apoptosis that may influence ovarian cancer risk. This marker was
selected based on its functional significance; the rs2228570 polymorphism is the only VDR polymorphism that has distinct structural
consequencies for the VDR protein. Although the association of the rs2228570 T allele with ovarian cancer risk found in this pooled
analysis is modest, it may reflect a true biological relation.
Impact
Ovarian cancer is a fatal gynecologic malignancy largely because of the absence of screening methods for its early detection. The
discovery of common genetic variants, such as the VDR FokI polymorphism, to assist in the identification of women at increased risk
of ovarian cancer holds great promise. Considering the possible value of synthetic vitamin D analog use in cancer treatment, our
findings also could be useful for the future investigations of individualized therapeutic strategies.
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The association of invasive ovarian carcinoma risk with the functional polymorphism rs2228570
(aka rs10735810; FokI polymorphism) in the vitamin D receptor (VDR) gene was examined in
1820 white non-Hispanic cases and 3479 controls in a pooled analysis of five population-based
case-control studies within the Ovarian Cancer Association Consortium. Odds ratios (ORs) and
95% confidence intervals (CIs) were estimated using unconditional logistic regression. Carriers of
the rare T allele were at increased risk of ovarian carcinoma compared to women with the CC
genotype in all studies combined; each copy of the T allele was associated with a modest 9%
increased risk (OR=1.09; 95% CI:1.01–1.19; p=0.04). No significant heterogeneity among studies
was observed (p=0.37) and, after excluding the dataset from the Hawaii study, the risk association
for rs2228570 among replication studies was unchanged (OR=1.09; 95% CI: 1.00–1.19; p=0.06).
A stronger association of rs2228570 with risk was observed among younger women (aged < 50
years versus 50 years or older) (p=0.04). In all studies combined, the increased risk per copy of the
T allele among younger women was 24% (OR=1.24; 95% CI: 1.04–1.47; p=0.02). This
association remained statistically significant after excluding the Hawaii data (OR= 1.20; 95% CI:
1.01–1.43; p=0.04). No heterogeneity of the association was observed by stage (p= 0.46), tumor
histology (p=0.98), or time between diagnosis and interview (p=0.94). This pooled analysis
provides further evidence that the VDR rs2228570 polymorphism might influence ovarian cancer
susceptibility.
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Introduction
In the past decade, there has been growing interest in a causal role of vitamin D in the
incidence of chronic disease, including cancer. 1 In an early ecologic study, Lefkowitz and
Garland 2 reported higher ovarian cancer mortality associated with lower regional sunlight
exposure in the US. This result was confirmed in several subsequent ecologic analyses. 3
The plausibility that dietary vitamin D is involved in ovarian cancer etiology is enhanced by
its inverse association with breast 4,5 and colon cancers, 6,7 malignancies with possible
etiologic similarities to ovarian cancer. 8 Although dietary studies of vitamin D and disease
risk are limited because of the influence of sunlight exposure, at least one case-control study
reported an inverse association of dietary vitamin D with ovarian cancer risk. 9 A possible
association of ovarian cancer risk with vitamin D exposure is supported by laboratory
investigations demonstrating that vitamin D and its synthetic analogs inhibit growth and
induce apoptosis in ovarian cells in culture and in animal models of ovarian cancer. 10–12
Most of the actions of vitamin D are mediated by the vitamin D receptor (VDR), a nuclear
transcription factor. 10,13,14 VDR is present in normal ovarian epithelium, human ovarian
tumors, and in human ovarian cancer cell lines. Overall, 83% of the normal ovarian surface
epithelium is VDR-immunoreactive. 14 Among polymorphisms in the vitamin D receptor
(VDR) gene described to date, rs2228570 (aka rs10735810) is the only single nucleotide
polymorphism (SNP) that has been shown to affect the VDR protein structure (reviewed in
Uitterlinden et al.15). This SNP is also known as the FokI polymorphism due to the presence
or absence of a restriction enzyme site. 15 It is a coding non-synonymous SNP in the
translational initiation codon that determines the formation of two protein variants: a longer
version of the VDR protein that corresponds to the T allele and a form shortened by three
amino acids corresponding to the C allele. Several in vitro studies showed that the shortened
VDR form was more effective in transactivation of the vitamin D signal. 16–18 In addition,
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the rs2228570 SNP has not been found to be in linkage disequilibrium with any other
polymorphisms in the VDR gene. 15
Previously, we reported that the VDR rs2228570 SNP may be an ovarian carcinoma
susceptibility marker. 19 Among white non-Hispanic women, compared to CC, the CT and
TT genotypes were associated with a more than two-fold increased risk [CT: odds ratio
(OR) = 2.5; 95% confidence interval (CI):1.3–4.8 and TT: odds ratio (OR) = 2.1; 95%CI:
0.8–5.2]; and the per allele increased risk was 56% (95% CI:1.01–3.41; p for trend=0.04).19
In the present study, limited to non-Hispanic white women with invasive ovarian carcinoma,
we present a replication analysis of our putative significant findings by including four
additional studies within the Ovarian Cancer Association Consortium (OCAC), a forum for
researchers to evaluate promising genetic associations with ovarian cancer with increased
power. 20
Material and Methods
Study Design and Population
This pooled analysis of five population-based studies from the US (GEOCS, Stanford, CA
and HAW, Honolulu, HI) and Europe (MALOVA, Denmark, and SEARCH and UKOPS,
United Kingdom) included 1820 cases with primary histologically-confirmed invasive
ovarian carcinoma and 3479 controls. Control subjects were randomly selected from the
same geographical area as cases. Eligibility criteria for controls included age 18 years or
older, no prior history of ovarian cancer, and having at least one intact ovary. All cases and
controls were white non-Hispanic women. A detailed description of the studies has been
previously published 21–25 and is summarized in Table 1. Epidemiological data were
collected using structured questionnaires that included socio-demographic and health-related
information, menstrual, reproductive and gynecological histories. OCAC members
submitted their epidemiological data through a secure website to Duke University where the
variables have been reviewed, cleaned, and merged. All studies were approved by the
review boards and ethics committees of their parent institutions, and written informed
consent was obtained from all participants. In addition, Duke University has Institutional
Review Board approval as a data coordinating center.
Genotyping
Genotyping for European studies and one US study was performed in the UK at Cambridge
University (SEARCH and GEOCS) and University College London (MALOVA, and
UKOPS). Genotyping for the HAW was conducted at the Cancer Research Center of
Hawaii, USA. In all laboratories, genotyping was performed using 5’ nuclease TaqMan
allelic discrimination assay (TaqMan, Applied Biosystems). We used the following quality
control criteria to measure the acceptability of the genotyping results: (1) >3% sample
duplicates included, (2) concordance rate for duplicate samples ≥ 98%, (3) overall call rate
(by study) >95% and (4) call rate >90% for each 384-well plate and (5) cases and controls
intermixed on each plate. All five studies met each of the criteria. Gene and allele
nomenclature was according to the National Center of Biotechnology Information.
Statistical analysis
Statistical analyses were performed using the SAS statistical package (SAS release 9.2, SAS
Institute Inc., Cary, NC). The chi-square test for association was used to compare the allele
frequency distributions among controls across studies, and the chi-square test for goodness-
of-fit was used to test consistency with the Hardy-Weinberg equilibrium for each study and
overall. The association of the rs2228570 polymorphism with ovarian carcinoma risk was
assessed using multivariate logistic regression models. ORs and 95% CIs were estimated
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separately for heterozygous and homozygous variant T allele carriers, using women with the
CC genotype as the reference group. We also performed genetic analyses testing a log-
additive model in which genotype was categorized by three levels (0, 1 and 2) representing
number of variant alleles. In addition, we compared risk among heterozygotes and
homozygote T allele carriers combined (testing a dominant genetic model) and among
women with the TT genotype compared to the CC and CT genotypes combined (testing a
recessive genetic model). Based on the Akaike Information Criterion (AIC), the log-additive
and dominant models provided better fit for the data than the recessive model.
To establish potential confounders, the distribution of the rs2228570 genotype among cases
and controls was examined by the following variables associated with ovarian cancer risk:
age, gravidity, parity, menopausal status, history of tubal ligation, hysterectomy, and use of
contraceptive and menopausal hormones. All models in the pooled analysis and by study
were adjusted for age and menopausal status, the only variables that were associated with
rs2228570 genotype. Heterogeneity of effects by study was examined using two different
methods. First, we included study site as a fixed effect covariate and evaluated heterogeneity
of the association of the rs2228570 SNP with risk by study, using a Wald test of the
genotype-study interaction term. Second, we included study site as a random effect using
SAS GLIMMIX procedure. The results were the same; only the fixed effect results are
presented. Ovarian cancer defined by stage (FIGO stages I-II versus III-IV), histological
type (serous, mucinous, endometrioid, clear cell, and other), and time between diagnosis and
interview (<6 months versus ≥ 6 months) were compared against controls in a polytomous
logistic regression model. Heterogeneity of the association of the rs2228570 genotype with
risk by age, menopausal status, stage, histological type, and time between diagnosis and
interview was evaluated using the Wald test comparing group-specific parameters for the
rs2228570 genotype in the logistic regression models. Analyses were conducted for each
study separately and for all studies combined. Data were analyzed with and without the
inclusion of HAW study to test the independent association of the rs2228570 genotype with
risk in the replication studies. All p-values were based on two-tailed tests. We evaluated
statistical significance at the 5% level. Although the initial study was small, the addition of
four independent studies increased the statistical power to 90% under a log-additive model
to detect an OR of 1.15 or higher. We also estimated an overall odds ratio for the TT
compared to the CC genotype group combining all published studies and the studies
presented in this manuscript using random effect meta-analysis techniques. 26
Results
The mean age of cases (56.7 years; SD=10.5; range: 20–91) and controls (56.6 years;
SD=10.7; range 20–86) was similar. The allele distribution among controls did not
significantly deviate from Hardy-Weinberg equilibrium in each study or in all studies
combined (p’s ≥ 0.10) (Table 1). Minor allele frequencies among controls ranged from 0.36
to 0.38 with no statistically significant differences in genotype distribution by study
(p=0.49) (Table 1).
Table 2 presents the rs2228570 association with ovarian cancer risk among cases by study
and in all studies combined. In all studies combined, the T allele of the rs2228570 variant
was significantly associated with invasive ovarian carcinoma risk (per allele OR=1.09; 95%
CI: 1.01–1.19; p=0.04 and dominant OR=1.14; 95% CI: 1.01–1.28; p=0.03). The OR for the
association of the T allele with risk remained unchanged when the Hawaii data were
excluded, although the confidence interval included unity (per allele OR=1.09; 95% CI:
1.00–1.18; p=0.06). No significant heterogeneity in the association of the rs2228570
genotype with risk across studies was observed in the log additive or dominant models.
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In Table 2 (last row), we included previously published results for the non-Hispanic white
women from the HAW study that included 15 women with borderline epithelial ovarian
tumors. Exclusion of cases with ovarian tumors classified as borderline malignant from the
HAW study weakened the association of the T allele with risk. However the association
remained significant in the dominant genetic model when only invasive tumors were
included (OR=2.19; 95%CI: 1.07–4.47; p=0.03). In addition to the HAW study, statistically
significant increased ovarian cancer risk associated with the T allele was observed among
the SEARCH study heterozygotes (OR=1.24; 95% CI:1.02–1.52; p for pair-wise comparison
with the CC genotype = 0.03).
There was a significant interaction between genotype and age (p=0.04 for the log-additive
and p=0.03 for the dominant model) (Table 3). The association of the T allele with risk
among younger women (< 50 years old) was statistically significant with the highest risk
among T allele homozygotes (OR=1.47; 95% CI: 1.02–1.12; p=0.04); no statistically
significant associations were observed among older women (≥ 50 years old). Figure 1
presents a forest plot for the association of the rs2228570 genotype with risk among women
< 50 years old by study. Although the association of the rs2228570 genotype with risk
among premenopausal women was stronger than among postmenopausal women, the
interaction of genotype and menopausal status was not statistically significant (p=0.11)
(Table 3). No statistically significant heterogeneity of effects was observed by histology (p=
0.98), stage of disease (p=0.46), or time between diagnosis and interview (6 months versus
more than 6 months) (p=0.94) (data not shown).
Discussion
In this pooled analysis of five population-based case-control studies, we found a 9%
increased risk of invasive ovarian carcinoma associated with each copy of the VDR
rs2228570 T allele. Ovarian cancer risk associated with the T allele was higher among
younger women. No heterogeneity of the genetic association was observed across tumor
histological subtypes, disease stage, or subgroups by time between diagnosis and interview.
In our initial study, 19 we found a 56% increased ovarian carcinoma risk per T allele (95%
CI: 1.01–3.41; p for trend=0.04). In addition, a significant association of this SNP with
ovarian cancer risk was recently reported by Tworoger et al. 27 (OR for T allele
homozygotes = 1.26; 95% CI: 1.01–1.57; p for trend=0.03) in a pooled analysis of 1473
cases and 2006 controls. However, the original HAW 19 study and the analysis by Tworoger
et al. 27 included women with borderline malignancy tumors. Excluding women with
borderline ovarian neoplasms from the analyses resulted in a widening of the confidence
intervals in the HAW study (OR=1.55; 95% CI: 0.98–2.47) and in the study by Tworoger et
al. 27 (OR=1.21; 95% CI: 0.96–1.53). A smaller study of 168 invasive ovarian carcinoma
and 321 controls by Clendenen et al. 28 did not find a significant association. In the current
pooled analysis, the risk estimate for rare allele homozygotes (OR=1.16; 95% CI: 0.97–
1.39) was similar to that reported by Tworoger et al. 27 In a meta-analysis of the current
studies (HAW, MAL, SEARCH, GEOCS, and UKOPS) and studies published by Tworoger
et al. 27 (NHS I and II, WHS, and NECC) and Clendenen et al. 28, the summary OR
comparing ovarian carcinoma risk for the VDR rs2228570 rare allele homozygotes (TT
genotype) versus common allele homozygotes (CC genotype) was 1.20 (95% CI: 1.05–1.38;
p=0.009).
Although the association of the rs2228570 T allele with ovarian cancer risk observed in our
pooled analysis is modest, it may reflect a true underlying biological phenonemon related to
disease development. The vitamin D signaling pathway is involved in a wide variety of
biological processes, including cell proliferation, differentiation and apoptosis (reviewed by
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Deeb et al. 29), and has the potential to influence ovarian cancer development. Rs2228570 is
the only VDR polymorphism that has distinct structural consequencies for the VDR protein.
30 The C to T nucleotide change results in a 424-amino acid VDR protein compared with a
longer 427-amino acid protein in the presence of the C allele. Functional studies showed that
the shorter protein has a 1.7-fold higher transactivation of the vitamin D response element of
the 24-hydrolase gene than the longer protein.15;31 In addition, Jurutka et al.17
demonstrated that the 424 amino acid VDR variant interacted more efficiently with the
transcription factor TFIIB. It is important to note that rs228570 is an independent genetic
marker as it is not in linkage disequilibrium with any of the other polymorphisms in the
VDR gene.
A stronger association of rs2228570 with risk among younger and premenopausal women
might be a result of effect modification of vitamin D expression by age 32,33 and estrogen
levels.34An age-related reduction in the vitamin D receptor has been reported. 32 VDR is a
known estrogen-responsive gene. 34 Estrogen has been reported to increase VDR gene
expression in intestinal mucosa, uterus, and liver in studies in animal models and in T 47D
human breast cancer cells. 35 Estrogen administration in women resulted in increased
mRNA expression of VDR. 35 It is plausible that the role of the rs2228570 polymorphism in
ovarian carcinoma risk might be more pronounced among younger, mostly premenopausal,
women who have higher vitamin D levels and greater amounts of VDR.
The strengths of this investigation are the population-based nature of the studies included,
histological confirmation of all cases, and stringent genotyping quality control procedures
established by the OCAC. 24 Population stratification might have influenced the results of
our investigation, and a false-positive association is possible. To minimize the population
stratification effects, this study included only white non-Hispanic women from developed
countries with comparable ovarian cancer incidence rates, and women were only compared
within geographical areas. Another strength is that the sample size was large and the allele
frequency was relatively high. It is also important that the rs2228570 SNP is not in LD with
any other polymorphism. Although one study (SEARCH) included prevalent cases, there
was no heterogeneity of effects among incident and prevalent cases (women diagnosed <6
months prior to participation versus ≥ 6 months after diagnosis) indicating survival bias was
minimal. However, the power was limited to examine gene-environment interactions. Larger
studies are required to explore the potential effect modification of the rs2228570 SNP-
ovarian cancer risk association by BMI, exogenous hormone use, gravidity/parity, anti-
inflammatory drug use, and other factors. It would also be of interest to identify differences
in genetic associations between invasive and borderline malignancy neoplasms in future
analysis. It may be possible in the future to explore the hypothesis that the association of the
rs2228570 genotype with risk might be modified by vitamin D status, 30 but it is likely that
this will need to be analysed in studies with prospectively collected serum samples.
In conclusion, VDR rs2228570 is a functional polymorphism that may play a role in ovarian
carcinogenesis through regulation of cell proliferation, apoptosis, and angiogenesis. Our
pooled analysis is the first report of effect modification of the rs2228570 association with
risk by age, with stronger associations among younger women.
Abbreviations used
SNP single nucleotide polymorphism
OR odds ratio
CI 95%confidence interval
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VDR vitamin D receptor gene
OCAC Ovarian Cancer Association Consortium
AIC Akaike Information Criterion
MALOVA Malignant Ovarian Cancer Study, Denmark
SEARCH Studies of Epidemiology and Risk Factors in Cancer Heredity: Ovarian
Cancer Study, United Kingdom
GEOCS Genetic Epidemiology of Ovarian Cancer Study, California, United States
HAW Hawaii Ovarian Cancer Study, Hawaii, United States
UKOPS United Kingdom Ovarian Cancer Population Study
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Forest plot of the ORs and 95% Cls comparing invasive ovarian carcinoma risk among
women < 50 years of age associated with the VDR rs2228570 rare allele homozygotes (TT
genotype) versus common allele homozygotes (CC genotype) for 4 studies included in the
current pooled analysis (UKOPS study participants were excluded because all were >50
years of age). The summary OR=1.47; 95% Cl: 1.02–2.12; p=0.04.
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Forest plot of the ORs and 95% Cls comparing ovarian carcinoma risk for the VDR
rs2228570 rare allele homozygotes (TT genotype) versus common allele homozygotes (CC
genotype) for 5 studies included in the current pooled analysis (HAW, MALOVA,
SEARCH, GEOCS, UKOPS) and published reports by Tworoger et al.27 (NHS I and II,
WHS, and NECC studies) and Clendenen et al.28 The summary OR=1.20; 95% Cl:1.05–
1.38; p=0.009.
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